Vinflunine Ditartrate

CHEMBL2105629 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1117.1 g/mol
LogP
Phase
4

Vinflunine ditartrate is the ditartrate salt form of vinflunine, a third-generation fluorinated vinca alkaloid antineoplastic agent used for advanced urothelial carcinoma. The ditartrate salt provides aqueous solubility for intravenous administration. Its mechanism involves tubulin binding at the vinca domain with suppression of microtubule dynamic instability and inhibition of mitotic progression.

Masse moléculaire

1117,1000 g/mol

TPSA

364,00 Ų

Mécanisme d'action

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O

InChI

InChI=1S/C45H54F2N4O8.2C4H6O6/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44;2*5-1(3(7)8)2(6)4(9)10/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t26-,27+,36-,37+,38+,42+,43+,44-,45-;;/m0../s1

Molecular Formula

C53H66F2N4O20

HBD / HBA

10 / 25

Liaisons Rotatives

16

Atomes Lourds

79

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Vinflunine ditartrate is the ditartrate salt form of vinflunine, a third-generation fluorinated vinca alkaloid antineoplastic agent used for advanced urothelial carcinoma. The ditartrate salt provides aqueous solubility for intravenous administration. Its mechanism involves tubulin binding at the vinca domain with suppression of microtubule dynamic instability and inhibition of mitotic progression.

Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.

Yes, Vinflunine Ditartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105629. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16220212. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.